نتائج البحث

1

First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset*

المصدر: Cancer Science
Cancer Sci

مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, Lung Neoplasms, medicine.medical_treatment, Programmed Cell Death 1 Receptor, non‐small‐cell lung carcinoma, Pembrolizumab, Kaplan-Meier Estimate, Gastroenterology, Deoxycytidine, B7-H1 Antigen, Carboplatin, 0302 clinical medicine, Antineoplastic Agents, Immunological, Japan, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Anaplastic Lymphoma Kinase, Neoplasm Metastasis, Aged, 80 and over, Cross-Over Studies, Hazard ratio, General Medicine, Middle Aged, PD-L1 protein, Progression-Free Survival, Oncology, 030220 oncology & carcinogenesis, non-small-cell lung carcinoma, Carcinoma, Squamous Cell, Female, Original Article, Non small cell, pembrolizumab, Adult, medicine.medical_specialty, Paclitaxel, First line, Pemetrexed, Antibodies, Monoclonal, Humanized, Drug Administration Schedule, 03 medical and health sciences, Drug Therapy, Clinical Research, Internal medicine, medicine, Confidence Intervals, Humans, Lung cancer, Adverse effect, PD‐L1 protein, Aged, Chemotherapy, business.industry, Genes, erbB-1, Original Articles, medicine.disease, Survival Analysis, Gemcitabine, Confidence interval, Retraction, 030104 developmental biology, treatment outcome, Cisplatin, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4692f872031566a6ba7ec9528f7d1191Test
https://doi.org/10.1111/cas.15144Test

2

Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD ‐1 antibody

المؤلفون: Yuji Matsumoto, Yuichiro Ohe, Hidehito Horinouchi, Ryota Shibaki, Shuji Murakami, Noboru Yamamoto, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Tatsuya Yoshida

المصدر: Thoracic Cancer

مصطلحات موضوعية: non‐small cell lung cancer, Adult, Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Lung Neoplasms, Multivariate analysis, soluble PD‐L1, Pembrolizumab, Antibodies, Monoclonal, Humanized, Gastroenterology, Programmed cell death ligand 1, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Internal medicine, mental disorders, medicine, Humans, Anti‐PD‐1 antibody, In patient, Lung cancer, Aged, Aged, 80 and over, biology, business.industry, Hazard ratio, Original Articles, General Medicine, PD‐L1 TPS, Middle Aged, Prognosis, medicine.disease, Survival Analysis, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, biology.protein, Original Article, Female, Nivolumab, Antibody, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19fced2ae8c7ae9ecc4e68e52a492d5dTest
https://doi.org/10.1111/1759-7714.13721Test

3

Pembrolizumab as first-line treatment for metastatic uveal melanoma

المؤلفون: Guido Rindi, Daniela Orteschi, Maria Grazia Sammarco, Marcella Zollino, Carmela Grazia Caputo, Tommaso Dosa, Monica Maria Pagliara, Giovanni Schinzari, Ernesto Rossi, Giampaolo Tortora, Emilio Bria, Alessandra Cassano, Maria Antonietta Blasi, Gianluigi Petrone

المصدر: Cancer Immunology, Immunotherapy

مصطلحات موضوعية: Oncology, Adult, Male, Uveal Neoplasms, Cancer Research, medicine.medical_specialty, Immunology, Population, Programmed Cell Death 1 Receptor, Antineoplastic Agents, Pembrolizumab, Antibodies, Monoclonal, Humanized, Antibodies, Liver metastases, Uveal melanoma, Antineoplastic Agents, Immunological, Internal medicine, Monoclonal, medicine, 80 and over, Immunology and Allergy, Humans, Progression-free survival, Prospective Studies, education, Prospective cohort study, Humanized, Melanoma, Aged, Aged, 80 and over, education.field_of_study, Settore MED/06 - ONCOLOGIA MEDICA, business.industry, Standard treatment, Middle Aged, medicine.disease, Primary tumor, Progression-Free Survival, First line, Immunological, Immunotherapy, Female, Original Article, Nivolumab, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd2fe029f15bfffa3e34af4974084aeeTest
http://europepmc.org/articles/PMC6584707Test

4

PD ‐1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma

المؤلفون: Martin H.N. Tattersall, Peter P. Luk, Geoff McCowage, Tahlia Scheinberg, Fiona Bonar, Michael J. Sullivan, Rooshdiya Z. Karim, David Thomas, Anna Lomax, Vivek A Bhadri, Annabelle Mahar

المصدر: Cancer Reports

مصطلحات موضوعية: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, sarcoma, Adolescent, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Population, Bone Neoplasms, Soft Tissue Neoplasms, Pembrolizumab, Antibodies, Monoclonal, Humanized, Young Adult, Internal medicine, Alveolar soft part sarcoma, medicine, Humans, Young adult, education, Immune Checkpoint Inhibitors, Retrospective Studies, education.field_of_study, business.industry, Soft tissue sarcoma, Original Articles, Immunotherapy, medicine.disease, humanities, Treatment Outcome, Disease Progression, Original Article, Female, immunotherapy, Sarcoma, Neoplasm Grading, business, Progressive disease, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::187977c3ebf62e3b2083deceba0df132Test
https://doi.org/10.1002/cnr2.1327Test

5

Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody

المؤلفون: Kazushige Wakuda, Satoshi Ikeda, Masafumi Sata, Ryota Ushio, Kentaro Ito, Takashi Sato, Shigeru Tanzawa, Naoki Furuya, Makoto Nishino

المصدر: Thoracic Cancer
Thoracic Cancer, Vol 12, Iss 5, Pp 613-618 (2021)

مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Adult, Male, atezolizumab, non‐small cell lung cancer, medicine.medical_specialty, Lung Neoplasms, Pembrolizumab, Antibodies, Monoclonal, Humanized, lcsh:RC254-282, Cohort Studies, 03 medical and health sciences, anti‐PD‐L1, 0302 clinical medicine, Atezolizumab, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Humans, Lung cancer, Immune Checkpoint Inhibitors, Aged, Retrospective Studies, Aged, 80 and over, Performance status, business.industry, Anti pd 1, General Medicine, Original Articles, Middle Aged, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Confidence interval, 030104 developmental biology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Retreatment, Female, Original Article, Nivolumab, business, Cohort study

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12194075aa42c60389387090977b3ce3Test
https://pubmed.ncbi.nlm.nih.gov/33448648Test

6

Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy

المؤلفون: Mi Woo Lee, Sung Eun Chang, Woo Jin Lee, Jee Ho Choi, Hak Tae Kim, Chong Hyun Won, Ye Jin Lee

المصدر: Journal of Korean Medical Science

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Anti-programmed Cell Death-1 (PD-1) Therapy, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Pembrolizumab, Dermatology, Malignancy, Antibodies, Monoclonal, Humanized, Skin Diseases, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Programmed cell death 1, Neoplasms, medicine, Humans, 030212 general & internal medicine, Cutaneous Adverse Event, Lung cancer, Adverse effect, Aged, Retrospective Studies, Aged, 80 and over, biology, business.industry, Pruritus, Cancer, Antibodies, Monoclonal, General Medicine, Immunotherapy, Middle Aged, medicine.disease, Prognosis, Nivolumab, biology.protein, Original Article, Female, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d886ea2b24d63f064b2b8a19002764edTest
http://europepmc.org/articles/PMC6609422Test

7

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials

المؤلفون: Delvys Rodriguez-Abreu, Bilal Piperdi, Luis Paz-Ares, Jianxin Lin, Takayasu Kurata, Shirish M. Gadgeel, Balazs Halmos, Baerin Houghton, Marina Chiara Garassino, Ying Cheng, M. Catherine Pietanza, Hossein Borghaei, Corey J. Langer

المصدر: Cancer

مصطلحات موضوعية: Oncology, Adult, Cancer Research, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Pembrolizumab, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Agents, Immunological, non–small cell lung cancer, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, antineoplastic agents, Humans, 030212 general & internal medicine, Lung cancer, Aged, Randomized Controlled Trials as Topic, Aged, 80 and over, Chemotherapy, business.industry, Hazard ratio, Cancer, Original Articles, Middle Aged, medicine.disease, Carboplatin, combined drug therapy, programmed cell death ligand 1 protein (human CD274 protein), Pemetrexed, chemistry, Response Evaluation Criteria in Solid Tumors, Chest and Lung Disease, 030220 oncology & carcinogenesis, Original Article, pembrolizumab, Disease Site, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da398adb2787fa3bcc2db943dfc67e66Test
https://pubmed.ncbi.nlm.nih.gov/32914866Test

8

Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer

المؤلفون: Yoshitaka Inaba, Toyoaki Hida, Takehiro Uemura, Shiro Fujita, Akio Niimi, Hiroaki Kuroda, Hiromi Furuta, Naohiro Watanabe, Yusuke Kagawa, Katsuhiro Masago, Junichi Shimizu, Takeshi Kodaira, Yoshitsugu Horio

المصدر: Cancer Science

مصطلحات موضوعية: 0301 basic medicine, Oncology, Ablation Techniques, Male, Cancer Research, Lung Neoplasms, Programmed Cell Death 1 Receptor, Pembrolizumab, Disease, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Medicine, Lymph node, Immune Checkpoint Inhibitors, Aged, 80 and over, General Medicine, Middle Aged, Combined Modality Therapy, Progression-Free Survival, oligometastasis, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Disease Progression, Female, Original Article, pembrolizumab, Nivolumab, oligoprogression, Adult, medicine.medical_specialty, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Clinical Research, Internal medicine, Humans, Lung cancer, Aged, Retrospective Studies, nivolumab, business.industry, Retrospective cohort study, Original Articles, medicine.disease, Blockade, local therapy, 030104 developmental biology, Feasibility Studies, business, Progressive disease

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::524047b7a50279af120da86046974dfcTest
https://pubmed.ncbi.nlm.nih.gov/32770608Test

9

Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas

المؤلفون: Young Hyeh Ko, Won Seog Kim, Jiyeon Hyeon, Seok Jin Kim, Inju Cho

المصدر: Cancer Research and Treatment : Official Journal of Korean Cancer Association

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Epstein-Barr Virus Infections, Herpesvirus 4, Human, Lymphoma, Pembrolizumab, medicine.disease_cause, B7-H1 Antigen, 0302 clinical medicine, Antineoplastic Agents, Immunological, immune system diseases, Programmed cell death 1, hemic and lymphatic diseases, Molecular Targeted Therapy, Neoplasm Metastasis, biology, Lymphoma, Non-Hodgkin, Middle Aged, Immunohistochemistry, Treatment Outcome, 030220 oncology & carcinogenesis, Original Article, Female, Positive staining, Adult, medicine.medical_specialty, Antibodies, Monoclonal, Humanized, Virus, 03 medical and health sciences, Refractory, Internal medicine, PDL1, medicine, Biomarkers, Tumor, Epstein-Barr virus, Humans, Aged, Neoplasm Staging, business.industry, Epstein-Barr Virus Positive, medicine.disease, Epstein–Barr virus, 030104 developmental biology, Positron-Emission Tomography, biology.protein, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c10a3ef7bf7e3ca4f13afe4c7f230654Test
http://europepmc.org/articles/PMC6473267Test

10

Predictors of immunotherapy-induced immune-related adverse events

المؤلفون: Joshua Lakoff, Tara Baetz, Joobin Sattar, V. Sahai, Adi Kartolo

المصدر: Current Oncology
Volume 25
Issue 5
Pages 4047-410

مصطلحات موضوعية: 0301 basic medicine, Oncology, Adult, Male, medicine.medical_specialty, Lung Neoplasms, Programmed Cell Death 1 Receptor, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Antineoplastic Agents, Immunological, Renal cell carcinoma, Adrenal Cortex Hormones, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Humans, CTLA-4 Antigen, Key Words Predictors, Adverse effect, Lung cancer, Carcinoma, Renal Cell, Melanoma, Aged, Retrospective Studies, Aged, 80 and over, business.industry, advanced solid cancers, Retrospective cohort study, Odds ratio, Middle Aged, medicine.disease, Kidney Neoplasms, 030104 developmental biology, Nivolumab, 030220 oncology & carcinogenesis, immune-related adverse events, Original Article, Female, immunotherapy, business, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3838cf6896928326e7b6302c877baecTest

تنقيح النتائج